Abstract: The present invention relates to long acting glucagon-like peptide-1 and human glucose- dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.

Abstract: The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1)(7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure provides methods and systems for hyperparameter tuning and benchmarking.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: Apparatuses, methods, and systems for automatic detection of interfering cells are disclosed. One method includes monitoring, by each of a plurality of user equipment, one or more characteristic of received wireless signals, wherein the plurality of user equipment is located within a coverage area of a plurality of macro-cells of a wireless network, collecting the monitored one or more characteristics the of the received wireless signal, and adjusting operation of a macro-cell or at least one sector of a sectorized supercell base station based on the collected monitored one or more characteristics of the received wireless signals, wherein at least one sector of the sectorized supercell base station has a wireless signal coverage area that overlaps with the coverage area of plurality of macro-cells of the wireless network.

Abstract: Apparatuses, methods, and systems for generation of antenna tower structures are disclosed. One method includes receiving structure requirements of a tower, iterating a design of the tower, including selecting tower design features, determining a structural model from the structure requirements and the tower design features, defining an outline of the tower based on structure requirements and tower design features, defining nodal points of the design of the tower based on the outline, defining line-elements of the design of the tower based on the nodal points, performing low-order structural analysis based on the structural model and a modeled behavior assigned to the line-elements including determining a wind load for each line element, determining nodal displacements and material failure indices based at least on the wind load for each line element, and redetermining the structural model when the nodal displacements and material failure indices indicate failure.

Abstract: A method for providing a managed networking service for a cloud computing system enables users to consume managed virtualized network functions (VNFs) at edge locations. The method includes registering a plurality of third-party vendors for the managed networking service. The plurality of third-party vendors provide a plurality of VNFs for the managed networking service. The method also includes receiving user input from a user of the cloud computing system. The user input includes a request to deploy the plurality of VNFs at an edge location. The plurality of VNFs can be provided by different third-party vendors through the managed networking service. The method also includes causing the plurality of VNFs to be deployed on an edge device that is located at the edge location. The plurality of VNFs can be represented as logical entities in a database that is utilized by the managed networking service.

Abstract: The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.

Abstract: The disclosure relates to a 5G or 6G communication system for supporting a higher data transmission rate. For example, the disclosure relates to a method for switching a data session for an application, implemented in a user equipment with dual SIM. The method includes: determining a User Equipment (UE) Route Selection Policy (URSP) rule for a primary Subscriber Identity Module (SIM) and a secondary SIM. The method includes detecting a trigger for switching the data session of the application to the secondary SIM based on determination of the URSP rule, wherein the trigger includes one of a matching traffic descriptor, a dedicated network slice, a Quality of Service (QoS) rule and a user preference. The method includes configuring the secondary SIM for the DDS based on the trigger; and switching the data session of the application to the secondary SIM for continuing the data session.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: Apparatuses, methods, and systems for adaptive sectoring of a wireless base station are disclosed. An apparatus includes a base station, wherein the base station includes a communication processing system operative to perform baseband processing of receive or transmit baseband signals. The base station further includes a plurality of antennas, wherein the plurality of antennas are connected to the communication processing system, wherein a plurality of subsets of the plurality of antennas operate to form a plurality of sectors, wherein each sector of each subset of the plurality of antennas is operative to cover a coverage area as determined by a beamforming pattern formed by a subset of the plurality of antennas of the sector, wherein the coverage area of one or more of the sectors is adaptively selected based on an existing cell site located within the coverage area of the one or more sectors.

Abstract: A method for providing a managed networking service for a cloud computing system enables users to consume managed virtualized network functions (VNFs) at edge locations. The method includes registering a plurality of third-party vendors for the managed networking service. The plurality of third-party vendors provide a plurality of VNFs for the managed networking service. The method also includes receiving user input from a user of the cloud computing system. The user input includes a request to deploy the plurality of VNFs at an edge location. The plurality of VNFs can be provided by different third-party vendors through the managed networking service. The method also includes causing the plurality of VNFs to be deployed on an edge device that is located at the edge location. The plurality of VNFs can be represented as logical entities in a database that is utilized by the managed networking service.

Abstract: Apparatuses, methods, and systems for surveying a site are disclosed. One method includes transmitting, by a ground unit, wireless signals while a directionally adjustable beam-forming antenna of the ground unit changes a beam direction of the transmission of the wireless signals to N beam directions, wherein the directionally adjustable beam-forming antenna includes a known motion, receiving and measuring, by an elevated unit, a magnitude and phase of the wireless signals transmitted by the ground unit through the N beam directions, determining N complex receive power representations wherein each complex receive power representation includes the measured magnitude and phase of the received wireless signals corresponding with each of the N beam directions, and determining a receive power summation comprising performing a complex summation of the N complex receive power representations.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.